• Facebook
  • Mail
  • Assistenza tecnica
  • Contatti
  • FAQ
Lunar by General Electric - distribuito da Caresmed

lineaLunar

by GE Healthcare

  • Home
  • Gamma
  • Tutorial
  • Video
  • Pubblicazioni
  • News
  • Cerca
  • Menu Menu

Pubblicazioni

Ti trovi in:  Home » Pubblicazioni

Pubblicazioni scientifiche

La letteratura scientifica nell’ambito della tecnologia DXA.

A path model of sarcopenia on bone mass loss in elderly subjects

Aging is associated with decreases in muscle mass, strength, power (sarcopenia) and bone mineral density (BMD). The aims of this study were to investigate in elderly the role of sarcopenia on BMD loss by a path model, including adiposity, inflammation, and malnutrition associations…
View publication.

Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation...

This study tested the hypothesis that nutritional supplementation with whey protein (22 g), essential amino acids (10.9 g, including 4 g leucine), and vitamin D [2.5 μg (100 IU)] concurrent with regular, controlled physical activity would increase fat-free mass, strength, physical function, and quality of life, and reduce the risk of malnutrition in sarcopenic elderly persons.
View publication.

Performance of Edmonton Frail Scale on frailty assessment: its association with multi-dimensional geriatric conditions assessed with specific screening tools.

The aim of this study was to evaluate the performance of Edmonton Frail Scale (EFS) on frailty assessment in association with multi-dimensional conditions assessed with specific screening tools and to explore the prevalence of frailty by gender.
View publication.

Association between muscle mass and adipo-metabolic profile: a cross-sectional study in older subjects.

Sarcopenia, the decrease in muscle mass and function, may lead to various negative health outcomes in elderly. The association among sarcopenia with body adiposity and metabolic markers has rarely been studied in the elderly population, with controversial results. Aim of this study is evaluated the cross-sectional relationship between muscle mass loss and a composite variable of body adiposity and metabolic markers.
View publication.

Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study

For the growing numbers of obese elderly with diabetes, the glucagon-like peptide-1 (GLP-1) receptor analogue (liraglutide) appears a safe way to promote and maintain substantial weight loss. Given this background, the aim of this study was to assess the effect of the liraglutide treatment, at doses up to 3.0 mg per day, on the body composition, focusing on sarcopenia, in overweight and obese elderly with type 2 diabetes mellitus (T2DM).
View publication.

Sarcopenia and sarcopenic obesity in comparison: prevalence, metabolic profile, and key differences. A cross-sectional study in Italian hospitalized elderly

The aim of this study is to identify the prevalence, assess the metabolic profile, and key differences (versus healthy) in a cohort of subjects with sarcopenia (S) and in sarcopenic obesity (SO) hospitalized elderly.
View publication.

Approfondimenti

Whitepapers e report scientifici che ruotano attorno al mondo Lunar.

Using GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures

The management of osteoporosis underwent a paradigm shift in 1995 with the approval of the first bisphosphonate, risedronate. Since then, several other bisphosphonates have been approved, including alendronate, ibandronate, and zoledronate, as well as the first biologic treatment for osteoporosis, denosumab. These drugs reduce fracture risk by decreasing bone resorption. Their use is attributed to a significant reduction in the incidence and mortality of hip fractures since 1995.

GE Lunar Technology Advantages

DXA stands for Dual-Energy X-ray Absorptiometry. It is a measurement method that uses the differences in the absorption of high energy and low energy X-ray photons by different elements in a body to quantify the amount of bone and soft tissue in the body. For example, certain elements in bone minerals (e.g. calcium) will absorb more low-energy X-rays than the elements in soft tissue, enabling a precise and accurate estimate of bone mineral density (BMD). By using relevant algorithms, we can also use the same measured data to determine body composition due to the different density and composition of fat and lean tissue. Based on DXA technology, the GE Healthcare Lunar bone densitometry product portfolio (iDXA, Prodigy, and Aria) empowers physicians and clinicians to diagnose osteoporosis and fracture risk. iDXA and Prodigy may also perform body composition analysis (fat and lean tissue mass). After a DXA scan, the measured values are compared to a reference population at the sole discretion of the physician to achieve desired clinical results.

A New Bone Structure Assessment Technique Enhances Identification of Fracture Risk

The World Health Organization defines osteoporosis as a silent disease characterized by low bone mass (bone density) and microarchitectural deterioration of bone tissue leading to increased bone fragility and elevated risk of fracture. Worldwide, osteoporosis affects an estimated 200 million women and causes nearly nine million fractures annually. Globally, one in three women and one in five men over the age of 50 will experience a fracture due to osteoporosis with a subsequent decrease in quality of life and an excess mortality rate for hip fractures >20% in the first year- By 2050, the worldwide incidence of hip fracture in women is projected to increase by 240% and in men by 310%.

Advancements in DXA body composition analysis: Metabolic phenotyping with CoreScan

The classical definition of obesity is the accumulation of excess adipose tissue (fat) to the point where health is negatively impacted. Because it has historically been difficult to measure the amount of fat in the body, physicians have relied on indices such as body mass index (BMI). Measurement of BMI is attractive to clinicians because it is cost effective; however, BMI is not always a reliable indicator of metabolic disease. In fact, studies have shown that 30% of individuals with obese BMI are metabolically healthy, and 20% of subjects with healthy BMI have metabolic disease2. Better identification of metabolic risk requires that we look beyond BMI and consider metabolic phenotyping based on body composition measures.

Caresmed S.r.l.
Via Vialba, 50 – 20026 Novate Milanese (MI)
Tel. 02.40741546 – Fax 02.40055079
E-mail: info@caresmed.it

© Copyright 2020 - Caresmed S.r.l.
  • Informativa privacy e cookie
Scorrere verso l’alto

Questo sito web utilizza cookie per una migliore esperienza dell'utente. Continuando a navigare si accetta la nostra politica di utilizzo dei cookie.

OKApprofondisci

Impostazioni cookie e privacy



Come usiamo i cookie

Potremmo richiedere che i cookie siano attivi sul tuo dispositivo. Utilizziamo i cookie per sapere quando visitate i nostri siti web, come interagite con noi, per arricchire la vostra esperienza utente e per personalizzare il vostro rapporto con il nostro sito web.

Clicca sulle linguette a fianco per saperne di più. Puoi anche modificare alcune delle tue preferenze. Tieni presente che il blocco di alcuni tipi di cookie potrebbe influire sulla tua esperienza sui nostri siti web e sui servizi che siamo in grado di offrire.

Cookie essenziali del sito web

Questi cookie sono strettamente necessari per fornirti i servizi disponibili attraverso il nostro sito web e per utilizzare alcune delle sue funzionalità.

Poiché questi cookie sono strettamente necessari per la fruizione del sito web, non è possibile rifiutarli senza influire sul funzionamento del nostro sito. È possibile bloccarli o eliminarli modificando le impostazioni del browser e imporre il blocco di tutti i cookie su questo sito web.

• aviaCookieConsent
• wfwaf-authcookie
• wordpress_logged_in
• wordpress_sec

Cookie di Google Analytics

Questi cookie raccolgono informazioni che vengono utilizzate in forma aggregata per aiutarci a capire come viene utilizzato il nostro sito web o l'efficacia delle nostre campagne di marketing o per aiutarci a personalizzare il nostro sito web e la vostra applicazione al fine di migliorare la vostra esperienza.

Se non vuoi che monitoriamo le tue visite sul nostro sito puoi disabilitare il monitoraggio nel tuo browser qui:

Altri servizi esterni

Usiamo anche diversi servizi esterni come Google Webfonts, Google Maps e fornitori di video esterni. Poiché questi fornitori possono raccogliere dati personali come il tuo indirizzo IP, ti consentiamo di bloccarli qui. Si prega di essere consapevoli del fatto che questo potrebbe ridurre pesantemente la funzionalità e l'aspetto del nostro sito. Le modifiche avranno effetto una volta ricaricata la pagina.

Impostazioni per Google Webfont:

Impostazioni per Google Maps:

Vimeo and YouTube video embeds:

Informativa Privacy

Puoi approfondire le funzioni dei nostri cookie e le nostre politiche sulla privacy nella pagina informativa.

Informativa sul trattamento dei dati personali
Accettare le impostazioniNascondi solo la notifica